{"id":"desogestrel-ethinyl-estradiol","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-15","effect":"Breakthrough bleeding"},{"rate":"2-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":{"setId":"b716fd2a-b186-447a-85bd-6302284d14e5","title":"PIMTREA (DESOGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL) KIT [NORTHSTAR RX LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The progestin desogestrel inhibits the luteinizing hormone (LH) surge necessary for ovulation, while ethinyl estradiol suppresses follicle-stimulating hormone (FSH) to prevent follicle development. Together, these hormones also thicken cervical mucus and alter the endometrium to create a hostile environment for sperm and implantation.","oneSentence":"Desogestrel/ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:31:59.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"},{"name":"Acne vulgaris (in some formulations)"}]},"trialDetails":[{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":"Fertility","enrollment":24},{"nctId":"NCT06540079","phase":"NA","title":"BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotronik, Inc.","startDate":"2024-12-18","conditions":"Sinus Node Dysfunction, Bradycardia, Atrioventricular Block","enrollment":192},{"nctId":"NCT06852365","phase":"PHASE2","title":"Combined Oral Contraceptive Pill and Resistance Starch","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-06-10","conditions":"Metabolic Syndrome, Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT07393009","phase":"","title":"Studying Routine Patient Care With BIOTRONIK Devices That Allow a More Natural Heart Stimulation","status":"NOT_YET_RECRUITING","sponsor":"Biotronik SE & Co. KG","startDate":"2026-03-01","conditions":"Cardiac Pacing, Cardiac Pacemaker, Implantable Cardioverter Defibrillator","enrollment":1000},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT06229366","phase":"PHASE1","title":"[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-03","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma","enrollment":142},{"nctId":"NCT07258251","phase":"PHASE4","title":"Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","status":"NOT_YET_RECRUITING","sponsor":"The Task Force for Global Health","startDate":"2026-01-01","conditions":"Chronic Hepatitis B, Hepatitis B Virus Infection","enrollment":6000},{"nctId":"NCT06620237","phase":"NA","title":"BIO|MASTER.CSP Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotronik SE & Co. KG","startDate":"2024-10-04","conditions":"Cardiac Pacing, Artificial, Cardiac Pacemaker, Artificial, Cardiac Resynchronization Therapy Devices","enrollment":152},{"nctId":"NCT06334315","phase":"PHASE4","title":"Oral Contraceptive Pill (OCP) Pharmacogenomics","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-10-29","conditions":"Contraception, Pharmacogenomic Drug Interaction","enrollment":700},{"nctId":"NCT06318130","phase":"NA","title":"Comparison of Pacing Lead Design on Left Bundle Branch Pacing Outcomes: The LEAD_LBBP Randomized Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-01-01","conditions":"Pacemaker DDD","enrollment":210},{"nctId":"NCT05002738","phase":"PHASE4","title":"Desogestrel-containing COCP Pharmacokinetic Validation Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-09-10","conditions":"Contraception","enrollment":22},{"nctId":"NCT06148571","phase":"","title":"Left Bundle Branch Area Pacing in Heart Failure Patients With Ejection Fraction Below Normal","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2023-10-10","conditions":"Left Ventricular Ejection Fraction Less Then or Equal to 50percent","enrollment":200},{"nctId":"NCT02367846","phase":"PHASE4","title":"Assessing the Impact of Contraceptives on Bone Health Using 41Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Penn State University","startDate":"2015-01","conditions":"Other Disorders of Bone Development and Growth","enrollment":6},{"nctId":"NCT06011252","phase":"NA","title":"Pacing Characteristics of a Conventional Bipolar","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-01-01","conditions":"Symptomatic Bradycardia","enrollment":150},{"nctId":"NCT04943588","phase":"","title":"Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-11-01","conditions":"Hepatitis C, Chronic","enrollment":25000},{"nctId":"NCT05251363","phase":"NA","title":"BIOTRONIK Conduction System Pacing With the Solia Lead","status":"COMPLETED","sponsor":"Biotronik, Inc.","startDate":"2022-12-12","conditions":"Bradycardia, Atrioventricular Block, Left Bundle-Branch Block","enrollment":194},{"nctId":"NCT06867419","phase":"","title":"Metabolic Features Effects on FAST Score in MASLD Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-09-01","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease","enrollment":385},{"nctId":"NCT06386094","phase":"","title":"Cardiac Dysfunction in Patients with Fatty Liver Disease","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2023-07-15","conditions":"NAFLD, Cardiac Disease, Fatty Liver","enrollment":150},{"nctId":"NCT05350865","phase":"","title":"Thailand HDV Cohort","status":"RECRUITING","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2023-01-30","conditions":"HDV","enrollment":3152},{"nctId":"NCT03332966","phase":"","title":"Youth Experiences and Health Study","status":"RECRUITING","sponsor":"Finnish Institute for Health and Welfare","startDate":"2019-12-01","conditions":"Psychotic Disorders, Psychiatric Hospitalization, Prodromal Symptoms","enrollment":1000},{"nctId":"NCT06586983","phase":"","title":"Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-09-04","conditions":"Hepatitis B","enrollment":4500},{"nctId":"NCT05793502","phase":"","title":"Study on Effectiveness and Safety of LBBaP With Solia S and Selectra 3D Developed by BIOTRONIK","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2023-07-04","conditions":"Consented to Participate in the Trial and Signed an ICF, Patients With an Indication for PM Implantation or CRTP","enrollment":1000},{"nctId":"NCT04320849","phase":"","title":"Human Use Condition Study- Evaluation of Implanted Leads in Humans","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-06-01","conditions":"Pacemaker Malfunction","enrollment":117},{"nctId":"NCT06049992","phase":"NA","title":"STylet-driven vs. LumenlEss Lead in Left-Bundle-Branch Pacing","status":"UNKNOWN","sponsor":"Puerta de Hierro University Hospital","startDate":"2023-09-21","conditions":"Left Bundle-Branch Pacing","enrollment":120},{"nctId":"NCT01500473","phase":"PHASE2","title":"Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome","status":"TERMINATED","sponsor":"Children's Hospital Los Angeles","startDate":"2012-02","conditions":"Congenital Central Hypoventilation Syndrome","enrollment":1},{"nctId":"NCT04573543","phase":"","title":"The Role of Immune Semaphorins in NAFLD","status":"COMPLETED","sponsor":"University Hospital for Infectious Diseases, Croatia","startDate":"2020-09-01","conditions":"Non-Alcoholic Fatty Liver Disease, Immune Response, Biomarkers","enrollment":160},{"nctId":"NCT05999331","phase":"","title":"Elevated Initial APRI Value Was Associated With SALD","status":"UNKNOWN","sponsor":"Chinese Medical Association","startDate":"2019-01-01","conditions":"Liver Dysfunction, Sepsis-associated Liver Dysfunction","enrollment":160},{"nctId":"NCT03612973","phase":"NA","title":"Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Chronic Hepatitis c","enrollment":80},{"nctId":"NCT03197077","phase":"PHASE3","title":"Optimisation of Follicular Recruitment in IVM Cycles","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2017-11-01","conditions":"Infertility, Female, Polycystic Ovary Syndrome","enrollment":145},{"nctId":"NCT05605158","phase":"PHASE3","title":"Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-11","conditions":"Non Alcoholic Steatohepatitis","enrollment":56},{"nctId":"NCT05594186","phase":"NA","title":"Nonsurgical Management of Cesarean Scar Niche Related Abnormal Uterine Bleeding","status":"COMPLETED","sponsor":"Saudi German Hospital - Madinah","startDate":"2019-03-01","conditions":"Intermenstrual Bleeding","enrollment":158},{"nctId":"NCT05503979","phase":"","title":"Elimination of Hepatitis C Virus Among Users of Substances","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2022-11-15","conditions":"Hepatitis C in Substance Users","enrollment":1000},{"nctId":"NCT03308916","phase":"NA","title":"Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers","status":"RECRUITING","sponsor":"Maja Thiele","startDate":"2017-10-06","conditions":"Liver Diseases, Alcoholic, Fibrosis","enrollment":6500},{"nctId":"NCT05433974","phase":"NA","title":"Pre-therapeutic Analysis of the Individual Radiosensitivity of Cancer Patients in Luxembourg (APRI-Lux): Prospective National Interventional Study With Minimal Risk","status":"UNKNOWN","sponsor":"Centre Francois Baclesse, Luxembourg","startDate":"2022-10-01","conditions":"Radiosensitivity, Cancer, Radiation Toxicity","enrollment":200},{"nctId":"NCT00778999","phase":"PHASE4","title":"Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10-01","conditions":"Infertility","enrollment":442},{"nctId":"NCT01005056","phase":"","title":"Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Contraception","enrollment":3838},{"nctId":"NCT01291004","phase":"PHASE1","title":"A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-01-31","conditions":"Follicle Development, Ovarian Follicle, Follicle Count","enrollment":206},{"nctId":"NCT01388491","phase":"PHASE2","title":"A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-10-31","conditions":"Hemostasis, Oral Contraceptive","enrollment":293},{"nctId":"NCT00544882","phase":"PHASE3","title":"A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-10-31","conditions":"Healthy","enrollment":61},{"nctId":"NCT01178125","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-08","conditions":"Contraception, Female Contraception","enrollment":2858},{"nctId":"NCT00946192","phase":"PHASE3","title":"Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-05","conditions":"Exercise-related Amenorrhea","enrollment":121},{"nctId":"NCT01058252","phase":"","title":"Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF","status":"UNKNOWN","sponsor":"Galaxy Pharma (Pvt) Limited","startDate":"2021-05","conditions":"Primary Infertility, Secondary Infertility, Low Responders","enrollment":30},{"nctId":"NCT04380493","phase":"","title":"The Use of the Transient Elastography Paediatric Probe, Compared to the M Probe, Indirect Biomarkers and Histology","status":"COMPLETED","sponsor":"Hospital Vall d'Hebron","startDate":"2015-05","conditions":"Elastography, Fibrosis, Liver, Pediatrics","enrollment":141},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":"Biological Availability","enrollment":68},{"nctId":"NCT02367833","phase":"PHASE4","title":"Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis","status":"COMPLETED","sponsor":"Penn State University","startDate":"2015-01","conditions":"Bone; Disorder, Development and Growth","enrollment":60},{"nctId":"NCT03212521","phase":"PHASE3","title":"Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-07","conditions":"Hepatitis C Virus (HCV)","enrollment":230},{"nctId":"NCT03953716","phase":"PHASE4","title":"Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy（LLLT） for Primary Dysmenorrhea（PD）","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-06-22","conditions":"Primary Dysmenorrhea, Traditional Chinese Medicine, Light","enrollment":480},{"nctId":"NCT02037867","phase":"","title":"Nottingham Community Liver Biomarkers Cohort","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2013-05","conditions":"Chronic Liver Disease, Alcohol Use Disorder, Type 2 Diabetes","enrollment":2000},{"nctId":"NCT00204438","phase":"NA","title":"Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2002-02","conditions":"Contraception","enrollment":45},{"nctId":"NCT01809665","phase":"","title":"ProMRI PROVEN Master Study","status":"COMPLETED","sponsor":"Biotronik SE & Co. KG","startDate":"2013-06","conditions":"Safety of MR (Magnetic Resonance) Conditional CRT-pacemakers and ICDs","enrollment":174},{"nctId":"NCT01638767","phase":"PHASE4","title":"NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles","status":"TERMINATED","sponsor":"Clinique Ovo","startDate":"2012-07","conditions":"Infertility","enrollment":7},{"nctId":"NCT01252186","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women","status":"COMPLETED","sponsor":"Teva Women's Health","startDate":"2010-11","conditions":"Hemostasis, Oral Contraceptive","enrollment":265},{"nctId":"NCT00624130","phase":"PHASE3","title":"Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":453},{"nctId":"NCT01076582","phase":"PHASE3","title":"Comparative Trial in Hormone Withdrawal Associated Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04","conditions":"Oral Contraceptive","enrollment":592},{"nctId":"NCT01616225","phase":"PHASE2, PHASE3","title":"Growth Hormone in Poor Responders to IVF Trial","status":"TERMINATED","sponsor":"Pacific Centre for Reproductive Medicine","startDate":"2012-06","conditions":"Infertility","enrollment":60},{"nctId":"NCT01310647","phase":"PHASE2","title":"Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2011-06","conditions":"Ovarian Diseases","enrollment":66},{"nctId":"NCT00823004","phase":"PHASE1, PHASE2","title":"Antagonist/Letrozole in Poor Responders","status":"COMPLETED","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-06","conditions":"Ovarian Stimulation","enrollment":120},{"nctId":"NCT01185678","phase":"","title":"Data on Oral Contraceptives Compliance in Non Stop Regimen","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Contraception","enrollment":8416},{"nctId":"NCT00826839","phase":"PHASE4","title":"Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2009-01","conditions":"Infertility","enrollment":""},{"nctId":"NCT01466673","phase":"PHASE4","title":"An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.,Thailand","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":201},{"nctId":"NCT01054586","phase":"","title":"Fosamprenavir in Pts With Hepatic Impairment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":167},{"nctId":"NCT00612508","phase":"NA","title":"Hormonal Contraception and Vaginal Health","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptive Usage, Vaginal Epithelial Disruption","enrollment":14},{"nctId":"NCT01298128","phase":"NA","title":"NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment","status":"TERMINATED","sponsor":"University of Toronto","startDate":"2006-02","conditions":"Infertility, In-vitro Fertilization","enrollment":70},{"nctId":"NCT01588873","phase":"PHASE4","title":"Contraceptive Pill and Hormonal Vaginal Ring in Women With Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"University of Oulu","startDate":"2012-04","conditions":"Adverse Effect of Oral Contraceptives, Sequela","enrollment":42},{"nctId":"NCT01482338","phase":"PHASE4","title":"Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2011-06","conditions":"Premenstrual Syndrome","enrollment":90},{"nctId":"NCT01087879","phase":"NA","title":"The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2007-10","conditions":"Contraception","enrollment":45},{"nctId":"NCT01384331","phase":"PHASE4","title":"New Treatments for Troublesome Bleeding in Implanon Users","status":"UNKNOWN","sponsor":"Family Planning Association New South Wales","startDate":"2011-07","conditions":"Menstrual Problem","enrollment":200},{"nctId":"NCT00236782","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-10","conditions":"Contraception","enrollment":1517},{"nctId":"NCT01256619","phase":"PHASE2","title":"Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2010-09","conditions":"Women With PMS","enrollment":61},{"nctId":"NCT00565240","phase":"NA","title":"Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2007-11","conditions":"Ovarian Follicle","enrollment":41},{"nctId":"NCT00185419","phase":"PHASE3","title":"A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-11","conditions":"Contraception","enrollment":842},{"nctId":"NCT00326404","phase":"PHASE3","title":"Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2006-05","conditions":"Contraception","enrollment":130},{"nctId":"NCT00675779","phase":"NA","title":"Efficacy Study of Atorvastatin in Pelvic Pain Relief in Women With Endometriosis","status":"UNKNOWN","sponsor":"Poznan University of Medical Sciences","startDate":"2008-04","conditions":"Endometriosis, Pain","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"desogestrel/ethinyl estradiol","genericName":"desogestrel/ethinyl estradiol","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desogestrel/ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity. Used for Contraception (prevention of pregnancy), Acne vulgaris (in some formulations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}